NDACAPSULE, DELAYED RELEASE
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
DULOXETINE (duloxetine) by Almatica Pharma is antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the cns. Approved for major depressive disorder, fibromyalgia, generalized anxiety disorder and 3 more indications. First approved in 2026.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Duloxetine is an SNRI (serotonin-norepinephrine reuptake inhibitor) antidepressant approved for major depressive disorder, fibromyalgia, generalized anxiety disorder, diabetic neuropathy, chronic back pain, and stress urinary incontinence. It works by potentiating serotonergic and noradrenergic activity in the CNS to produce antidepressant, anxiolytic, and central pain-inhibitory effects. The delayed-release capsule formulation was recently approved by Almatica Pharma in February 2026.
Launch
New launch in February 2026 represents opportunity for field build and market share capture in a competitive depression/anxiety space; team will be scaled for launch execution and ramp.
Mechanism of Action
antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.
Indications (6)
Worked on DULOXETINE at Almatica Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.